A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma

INTRODUCTION: Single-agent monoclonal antibody therapy against programmed death-ligand 1 (PD-L1) has modest effects in malignant pleural mesothelioma. Radiation therapy can enhance the antitumor effects of immunotherapy. Nevertheless, the safety of combining anti-PD-L1 therapy with stereotactic body...

Descripción completa

Detalles Bibliográficos
Autores principales: Rimner, Andreas, Adusumilli, Prasad S., Offin, Michael D., Solomon, Stephen B., Ziv, Etay, Hayes, Sara A., Ginsberg, Michelle S., Sauter, Jennifer L., Gelblum, Daphna Y., Shepherd, Annemarie F., Guttmann, David M., Eichholz, Jordan E., Zhang, Zhigang, Ritter, Erika, Wong, Phillip, Iqbal, Afsheen N., Daly, Robert M., Namakydoust, Azadeh, Li, Henry, McCune, Megan, Gelb, Emily H., Taunk, Neil K., von Reibnitz, Donata, Tyagi, Neelam, Yorke, Ellen D., Rusch, Valerie W., Zauderer, Marjorie G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801123/
https://www.ncbi.nlm.nih.gov/pubmed/36590015
http://dx.doi.org/10.1016/j.jtocrr.2022.100440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801123/
https://www.ncbi.nlm.nih.gov/pubmed/36590015
http://dx.doi.org/10.1016/j.jtocrr.2022.100440

Ejemplares similares